Baroness Greenfield was interviewed by Robyn Williams on Thursday 30th May, a Science journalist and broadcaster who presents RN’s The Science Show in Sydney. During the episode, they primarily discussed Neuro-Bio’s research on Alzheimer’s...
Baroness Greenfield was delighted to attend NeuRA in May 2024 as a special guest to discuss “Can Science be creative?” During this talk, she provides an insight on intersection between science and creativity, and guides us through her journey of...
NEURO-BIO LTD AND WORLDWIDE EXPERTS ON AD PUBLISH A NOVEL PERSPECTIVE IN ALZHEIMER’S & DEMENTIA: THE JOURNAL OF THE ALZHEIMER’S ASSOCIATION. Evidence for a novel neuronal mechanism driving Alzheimer’s disease, upstream of amyloid (Link to the paper) An...
Baroness Greenfield was interviewed by Ricard Glover on Tuesday 21st May, an Australian talk radio presenter, journalist and author. He is best known as presenter of the drive program on 702 ABC Sydney. During their interview, they discussed the impact of screen...
We are thrilled to announce that Baroness Greenfield is joining NeuRA (Neuroscience Research Australia) in Sydney next month. Baroness Greenfield will delve into the innovative heart of scientific discovery, as well as a personal and interactive chat with Carole...
Alzheimer’s Society is pleased to confirm that their retreat for early career dementia researchers will return in June 2024, and Baroness Greenfield is delighted to attend and to speak at the retreat. Click here to read more on the event and to book your place and...
The CSO at Aptamer group spoke recently in an interview with BioPharma APAC about Neuro-Bio’s ongoing partnership in which to develop Optimer binders to enable a lateral flow test for the early detection of Alzheimer’s disease. He also covered how a move...
Baroness Susan Greenfield sharing her perspective with Esther Reynal de St Michel Richardot on these important topics: Healthcare-related challenges that policy making is trying to address How it is impacting how innovations can reach patients The importance of having...
At Neuro-Bio, we’re thrilled at entering this next phase of development with Aptamer Group: the first phase proved productive and very promising. Now, this next stage takes us closer to realising a highly novel and much needed technology for detecting...
Our CEO Susan Greenfield and Operations Direction Sara Garcia-Rates, joined Xenopat for a face-to-face meeting in Barcelona where they shared the progress made for the Tecniospring Industry project “Development of a T14 Inhibitor for Treatment of ColoRectal Cancer”,...
